ASTU-045
/ Novalix, Aqemia
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
ASTU-045, a novel METTL3 inhibitor with anti-tumor activity in the MC38 syngeneic mouse model
(AACR 2026)
- "Strong target engagement was also observed in the spleen under both treatment conditions. In summary, we identified ASTU-045 as a novel, selective METTL3 inhibitor with high efficacy in the MC38 syngeneic model."
Preclinical • Oncology • METTL14 • METTL3
1 to 1
Of
1
Go to page
1